Cassava Sciences, Inc. (FRA:PX91)

Market Cap	132.47M
Revenue (ttm)	n/a
Net Income (ttm)	-90.37M
Shares Out	n/a
EPS (ttm)	-1.87
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	57
Open	2.796
Previous Close	2.608
Day's Range	2.796 - 2.796
52-Week Range	1.030 - 3.902
Beta	n/a
RSI	53.42
Earnings Date	Mar 3, 2026

About Cassava Sciences

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. Cassava Sciences, Inc. was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Te...

• Industry: Pharmaceutical Preparations
• Founded: 1998
• Employees: 30
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: PX91

Financial Performance

Financial numbers in USD